ArticleNAR cancer2022

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.

Anya Golder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.